1.Androgen abuse in sports.
David J HANDELSMAN ; Alison HEATHER
Asian Journal of Andrology 2008;10(3):403-415
Androgens remain the most effective and widely abused ergogenic drugs in sport. Although androgen doping has been prohibited for over 3 decades with a ban enforced by mass spectrometric (MS)-based urine testing for synthetic and exogenous natural androgens, attempts continue to develop increasingly complex schemes to circumvent the ban. A prominent recent approach has been the development of designer androgens. Such never-marketed androgens evade detection because mass spectrometry relies on identifying characteristic chemical signatures requiring prior knowledge of chemical structure. Although once known, designer androgens are readily detected and added to the Prohibited List. However, until their structures are elucidated, designer androgens can circumvent the ban on androgen doping. To combat this, in vitro androgen bioassays offer powerful new possibilities for the generic detection of unidentified bioactive androgens, regardless of their chemical structure. Another approach to circumvent the ban on androgen doping has been the development of indirect androgen doping, the use of exogenous drugs to produce a sustained increase in endogenous testosterone (T) production. Apart from estrogen blockers, however, such neuroendocrine active drugs mostly provide only transient increases in blood T. Finally the ban on androgen doping must allow provision for rare athletes with incidental, proven androgen deficiency who require T replacement therapy. The Therapeutic Use Exemption mechanism makes provision for such necessary medical treatment, subject to rigorous criteria for demonstrating a genuine ongoing need for T and monitoring of T dosage. Effective deterrence of sports doping requires novel, increasingly sophisticated detection options calibrated to defeat these challenges, without which fairness in sport is tarnished and the social and health idealization of sporting champions devalued.
Androgens
;
administration & dosage
;
Biological Assay
;
Designer Drugs
;
Doping in Sports
;
Humans
2.Androgen replacement therapy for hypogonadal men.
Yu-Gui CUI ; Yue JIA ; Fu-Song DI ; Xing-Hai WANG
National Journal of Andrology 2003;9(3):210-213
Male hypogonadism is a group of syndromes in clinic andrology characterized by complete or partial androgen deficiency. It can be divided into primary and secondary hypogonadism. Besides the etiological treatment, androgen replacement therapy should be adopted in all patients of primary hypogonadism and patients of secondary hypogonadism who do not have the need of having a child. For patient's benefits, androgen should be used and selected properly as there are so many androgen preparation at present.
Androgens
;
administration & dosage
;
deficiency
;
therapeutic use
;
Hormone Replacement Therapy
;
Humans
;
Hypogonadism
;
drug therapy
;
Male
3.Androgenic-anabolic steroids and the Olympic Games.
Asian Journal of Andrology 2008;10(3):384-390
Androgenic-anabolic steroids (AAS) have been misused by athletes at the Olympic Games, both before and after they were prohibited in sport in 1974. Systematic doping with AAS occurred in the German Democratic Republic (GDR) from 1965 to 1989 which assisted that country to win many medals at Olympic Games, especially in female events. Currently, AAS are the most frequent category of prohibited substances detected in the urine of athletes both globally and at the last two Summer Olympic Games. Scientific confirmation that AAS are effective in enhancing sports performance was difficult because ethical approval was difficult for research involving male subjects taking massive doses of androgens as some athletes and bodybuilders did. Methods to detect AAS have evolved gradually over the past three decades and currently, despite an impressive array of sophisticated analytical equipment and methods, anti-doping authorities and analytical scientists continue to face challenges as have occurred from the use by athletes of designer AAS during the past few years. The future development and use of selective androgen receptor modulators (SARMs) can be anticipated to pose problems in the years ahead. Endocrinologists should be aware that on occasions, replacement testosterone (T) therapy may be authorized in sport as a therapeutic use exemption (TUE) and these circumstances are discussed.
Anabolic Agents
;
administration & dosage
;
Androgens
;
administration & dosage
;
Chromatography, Gas
;
Doping in Sports
;
Humans
;
Mass Spectrometry
;
Radioimmunoassay
;
Spectrophotometry, Atomic
;
Sports
4.Pharmacologic management of female sexual dysfunction.
Journal of the Korean Medical Association 2016;59(2):136-143
In female sexual dysfunction (FSD), psychological and contextual factors significantly influence organic components of sexual response and behavior. The hormonal environment also affects FSD. Therefore, a tailored medical approach to each individual's sexual symptom is inevitable. This paper reviews currently available pharmacological treatment of FSD including the most recent advances and future targets in pharmacotherapy. In hormonal therapies for FSD, efficacy of estrogens and androgens on the treatment of vaginal atrophy, low sexual desire, and small subsets of genital arousal disorder, respectively, have been demonstrated. However, we need more data regarding long-term safety. There are two non-hormonal agents approved by the US Food and Drug Administration. Flibanserin has shown marginal benefit over placebo for the treatment of hypoactive sexual desire disorder. Ospemifen has shown beneficial effect on vulvovaginal pain from hormone related atrophy although it requires a longer period data to assess safety in other female genital organs, such as uterus and ovaries. Controversies still remain regarding hormonal therapies for FSD. Besides, some of the developing drugs still require more reliable safety and efficacy data. However, pharmacologic treatment of FSD is a promising field yet to be explored.
Androgens
;
Arousal
;
Atrophy
;
Drug Therapy
;
Estrogens
;
Female*
;
Genitalia, Female
;
Humans
;
Ovary
;
Sexual Dysfunctions, Psychological
;
United States Food and Drug Administration
;
Uterus
5.Hormonal replacement therapy and aging: Asian practical recommendations on testosterone supplementation.
Asian Journal of Andrology 2003;5(4):339-344
Profound and diffuse alterations in the production of gonadal and adrenal androgens as well as growth hormone are associated with aging. To convey this concept more appropriately, partial endocrine deficiency in the aging male (PEDAM) was introduced as a term for the phenomenon of hormonal alterations in the aging male. Hormones responsible for some of the manifestations associated with male aging are testosterone, growth hormone, dehydroepiansdrosterone (DHEA), melatonin, thyroid hormones and leptin. Of these, testosterone has been widely investigated and its beneficial and adverse effects on male bodily systems are relatively well established. However, a serious body of confusion and misunderstandings surrounding the diagnosis, treatment and monitoring of men suspected of having androgen deficiency has been raised. Therefore, it is timely to provide practical criteria for diagnosis and treatment to avoid misconception about the use of testosterone in the aging male. To provide an understanding and information of the issues, the following headings are summarized: (1) Important clinical consideration on testosterone supplementation in the aging male; (2) Asian practical recommendations on testosterone supplementation in the aging male.
Aging
;
Androgens
;
deficiency
;
Asia
;
Hormone Replacement Therapy
;
Humans
;
Male
;
Middle Aged
;
Practice Guidelines as Topic
;
Testosterone
;
administration & dosage
;
adverse effects
6.Triptolide reduces prostate size and androgen level on testosterone-induced benign prostatic hyperplasia in Sprague Dawley rats.
Yu-Rong WANG ; Yuan XU ; Zhen-Zhou JIANG ; Lu-Yong ZHANG ; Tao WANG
Chinese Journal of Natural Medicines (English Ed.) 2017;15(5):341-346
Benign prostatic hyperplasia (BPH) is an age-related disease of unknown etiology, characterized by prostatic enlargement coincident with distinct alterations in tissue histology. In the present study, we investigated whether triptolide can prevent testosterone-induced prostatic hyperplasia in rats. Castration was performed via the scrotal route after urethane aesthesia. BPH was induced in experimental groups by daily subcutaneous injections of testosterone propionate (TP) for two weeks. Triptolide was administered daily by oral gavage at a dose of 100 and 50 μg·kg for 2 weeks, along with the TP injections. On day 14, the animals were humanely killed by cervical dislocation after aesthesia. Prostates were excised, weighed, and used for histological studies. Testosterone and dihydrotestosterone (DHT) levels in serum and prostate were measured. The results showed that triptolide significantly reduced the prostate weight, and the testosterone and DHT levels in both the serum and prostate. Histopathological examination also showed that triptolide treatment suppressed TP-induced prostatic hyperplasia. In conclusion, triptolide effectively inhibits the development of BPH induced by testosterone in a rat model.
Androgens
;
blood
;
Animals
;
Diterpenes
;
administration & dosage
;
Drugs, Chinese Herbal
;
administration & dosage
;
Epoxy Compounds
;
administration & dosage
;
Humans
;
Male
;
Phenanthrenes
;
administration & dosage
;
Prostate
;
drug effects
;
growth & development
;
Prostatic Hyperplasia
;
blood
;
drug therapy
;
physiopathology
;
Rats
;
Rats, Sprague-Dawley
;
Testosterone
;
blood
;
Tripterygium
;
chemistry
7.Development of Rat Prostatitis Model by Oral Administration of Isoflavone and Its Characteristics.
Soo Mee KWON ; Sun Il KIM ; Dong Chan CHUN ; Nam Hoon CHO ; Bong Chul CHUNG ; Byung Wha PARK ; Sung Joon HONG
Yonsei Medical Journal 2001;42(4):395-404
Inflammation of the prostate can be induced experimentally in rats by the subcutaneous administration of estrogen. However, it is usually achieved at the price of some alteration in the sex steroid hormone balance and morphological changes in the prostate. In this study, a soy-extracted isoflavone mixture with weak estrogenic activity was administered orally in an attempt to induce prostatitis in a more physiologic way and to characterize the inflammation induced. A total of 36 male Sprague-Dawley rats, 8 weeks old, were divided into 2 groups. The control group was fed with only an AIN-76A diet containing no detectable phytoestrogen and the experimental group was fed with AIN-76A and a soy- extracted isoflavone mixture (genistein 60.0% and daidzein 19.6%), 300mg/kg body weight for 9 weeks. The sequential body weight and prostate weight at necropsy were measured. A histologic examination and histomorphometry assessed the changes in the prostate. The serum concentrations of testosterone and dihydrotestosterone were measured to estimate the effects on the androgen level. Intraprostatic concentrations of genistein and daidzein were measured by gas chromatography/ mass spectroscopy (GC/MS). While no sign of prostate inflammation was apparent in the control group, severe inflammatory changes in the stroma, increased epithelial detachment and inflammatory exudates within the glandular lumen of the dorsolateral prostate were observed in more than 80%(15/18) of the experimental group. However, there was no significant difference in the ventral prostate between the two groups. The daidzein and genistein concentrations in both the lateral and ventral prostates were significantly higher in the experimental group than in the control group where no isoflavone was detectable. In addition, the concentrations were much higher in the dorsolateral than in the ventral prostate. Although the body weight gain was not consistent in the experimental group, there were no significant differences in the prostate weight and serum androgen level between groups. In summary, when a soy-extracted genistein and daidzein-rich isoflavone mixture was administered orally into rats, prostatic inflammation with characteristic lobe specificity developed. The present method of inducing prostatitis seems to be a more physiologic than an estrogen-induced experimental model, and sequential pharmacokinetic studies might help in establishing this model as a more valuable tool in assisting future research in this field.
Administration, Oral
;
Androgens/blood
;
Animal
;
Body Weight/drug effects
;
Isoflavones/metabolism/*toxicity
;
Male
;
Organ Weight/drug effects
;
Prostatitis/*chemically induced/pathology
;
Rats
;
Rats, Sprague-Dawley
8.Prognostic value of PSA kinetics in locally advanced prostate cancer treated by maximal androgen blockade combined with brachytherapy.
Yong LUO ; Neng-Bao WEI ; Jia-Hui ZHAO ; Xin-Hao CUI ; Ming-Chuan LI ; Yun-Hua LIN ; Zhu HOU ; Yi-Li HAN ; Yong-Guang JIANG
National Journal of Andrology 2014;20(3):229-233
OBJECTIVETo evaluate the effect of post-treatment PSA kinetics on the prognosis of prostate cancer (PCa).
METHODSWe retrospectively reviewed the clinical data of 114 cases of locally advanced PCa treated by maximal androgen blockade (MAB) combined with brachytherapy, and analyzed the association of the changes in PSA kinetics with the prognosis of the patients.
RESULTSThe median survival time of the patients was 81 (15 - 144) months, with 1-, 3- and 5-year survival rates of 91. 23%, 78.07% and 68.42% , respectively. Univariate analysis indicated that the baseline PSA level, PSA nadir, the time of PSA decreasing to nadir, PSA doubling time, and the extent of PSA declining were all predictive factors for the survival time of the PCa patients. Multivariate analysis demonstrated that PSA nadir, the time of PSA decreasing to nadir, and the extent of PSA declining were three independent prognostic factors, which prolonged the long-term survival of the patients by 1.7, 3.2 and 6.8 times, respectively.
CONCLUSIONFor locally advanced PCa treated by MAB combined with brachytherapy, PSA nadir <1 micro g/L, the time to nadir <3 months, and the extent of PSA declining >96% are independent prognostic factors.
Aged ; Aged, 80 and over ; Androgens ; administration & dosage ; therapeutic use ; Brachytherapy ; Humans ; Male ; Middle Aged ; Prognosis ; Prostate-Specific Antigen ; metabolism ; Prostatic Neoplasms ; metabolism ; therapy ; Retrospective Studies
9.Oral Testosterone Undecanoate Capsules combined with Qilin Pills for late-onset hypogonadism in males.
Jun-Biao MAO ; Xiao-Gang CHEN ; Ding-Wen GUI ; Wei PENG ; Jie ZHENG
National Journal of Andrology 2017;23(5):455-458
Objective:
To investigate the clinical effects of oral Testosterone Undecanoate Capsules (TUC) combined with Qilin Pills (QLP) on late-onset hypogonadism (LOH) in men.
METHODS:
Sixty-three LOH patients meeting the inclusion criteria were randomly divided into a control group (aged [48.4 ± 6.2] yr, n = 32) and an experimental group (aged [47.2 ± 5.6] yr, n = 31) to be treated with oral TUC (80 mg, qd) and TUC + QLP (6g, tid), respectively, both for 3 months. Comparisons were made between the two groups of patients in the IIEF-5 scores, total testosterone (TT) levels, and scores in the Aging Males' Symptoms (AMS) scale before and after treatment.
RESULTS:
After treatment, the patients of the experimental group, as compared with the controls, showed a significantly increased IIEF-5 score (21.7 ± 5.8 vs 15.9 ± 4.7, P <0.05) and TT level ([16.7 ± 2.2] vs [13.1 ± 2.8] nmol/L, P <0.05), but a decreased AMS score (20.7 ± 5.7 vs 31.3±6.5, P <0.05).
CONCLUSIONS
TUC combined with Qilin Pills has a better effect and a lower rate of adverse reactions than TUC used alone in the treatment of late-onset hypogonadism in males.
Androgens
;
administration & dosage
;
adverse effects
;
Capsules
;
Drug Therapy, Combination
;
adverse effects
;
Drugs, Chinese Herbal
;
administration & dosage
;
adverse effects
;
Humans
;
Hypogonadism
;
blood
;
drug therapy
;
Male
;
Middle Aged
;
Testosterone
;
administration & dosage
;
adverse effects
;
analogs & derivatives
;
blood
10.Reversible Infertility Associated with Testosterone Therapy for Symptomatic Hypogonadism in Infertile Couple.
Jeong Kyoon BANG ; Jung Jin LIM ; Jin CHOI ; Hyung Jae WON ; Tae Ki YOON ; Jae Yup HONG ; Dong Soo PARK ; Seung Hun SONG
Yonsei Medical Journal 2013;54(3):702-706
PURPOSE: Androgen replacement therapy has been shown to be safe and effective for most patients with testosterone deficiency. Male partners of infertile couples often report significantly poorer sexual activity and complain androgen deficiency symptoms. We report herein an adverse effect on fertility caused by misusage of androgen replacement therapy in infertile men with hypogonadal symptoms. MATERIALS AND METHODS: The study population consisted of 8 male patients referred from a local clinic for azoospermia or severe oligozoospermia between January 2008 and July 2011. After detailed evaluation at our andrology clinic, all patients were diagnosed with iatrogenic hypogonadism associated with external androgen replacement. We evaluated changes in semen parameters and serum hormone level, and fertility status. RESULTS: All patients had received multiple testosterone undecanoate (NebidoR) injections at local clinic due to androgen deficiency symptoms combined with lower serum testosterone level. The median duration of androgen replacement therapy prior to the development of azoospermia was 8 months (range: 4-12 months). After withdrawal of androgen therapy, sperm concentration and serum follicle-stimulating hormone level returned to normal range at a median 8.5 months (range: 7-10 months). CONCLUSION: Misusage of external androgen replacement therapy in infertile men with poor sexual function can cause temporary spermatogenic dysfunction, thus aggravating infertility.
Adult
;
Androgens/administration & dosage/adverse effects/*therapeutic use
;
Azoospermia/*drug therapy
;
Erectile Dysfunction/drug therapy
;
Humans
;
Hypogonadism/*drug therapy
;
Infertility, Male/*chemically induced/drug therapy
;
Male
;
Oligospermia/*drug therapy
;
Testosterone/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use